ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
CausalCellInfer: Prioritizing Cell-Type-Specific Disease Associations From Genetically Predicted Transcriptomes in Biobank Cohorts.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Integrating single-cell RNA sequencing(scRNA-seq) with the phenotypic depth of population-scale biobanks is essential for elucidating the cellular basis of complex diseases. However, this is hindered by limited scRNA-seq sample size and the lack of cellular resolution in biobanks. We present CausalCellInfer, a scalable computational framework bringing cellular resolution to bulk and genotype-imputed transcriptomes. CausalCellInfer employs an invariant causal prediction-inspired method(scRNA-seq-based invariant generalized covariance measure, scI-GCM) to select environment-stable marker genes, a parsimonious deep neural network for cell-fraction deconvolution, and regularized matrix completion to reconstruct cell-type-specific (CTS) expression profiles. This design is optimized for biobank-scale data with technical heterogeneity and limited gene overlap. Validated across simulated data, pseudo-bulk and real peripheral blood mononuclear cell (PBMC) datasets, CausalCellInfer demonstrated superior accuracy and efficiency over existing methods. Applied to ∼500 000 UK Biobank (UKBB) participants across 29 traits, it captured known pathological shifts, such as reduced pancreatic β-cell proportions in type 2 diabetes, and identified novel biological signals, including disrupted excitatory neuron-oligodendrocyte interactions in depression. Inferred CTS differential expression patterns showed significant concordance with independent single-cell studies and were enriched for Open Targets disease genes. Overall, CausalCellInfer bridges single-cell insights and population-scale genomics, enabling systematic discovery of putative disease mechanisms at cellular resolution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.